MDxHealth SA (MDXH) News

MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance

            MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenuesand Raises 2024 Revenue Guidance...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mdxhealth to Present at Upcoming Investor Conferences

        Mdxhealth to Present at Upcoming Investor Conferences IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024...

MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed

MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase...

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL...

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2...

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]